



Cancer Project 2015 – 2017 Standing Committee

COMMITTEE MEMBERS

David Cella, PhD

Co-Chair

Professor and Chair, Northwestern University
Evanston, Illinois

Dr. Cella earned his bachelor's degree in Psychology from Northwestern University and his PhD in Clinical Psychology from Loyola University of Chicago. He completed a post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center and then joined the faculty there. In 1987, he assumed the position of Director of Psychosocial Oncology at Rush Presbyterian-St. Luke's Medical Center. In 1997, he moved to Evanston Northwestern Healthcare to direct its new Center on Outcomes, Research and Education (CORE), and joined the Robert H. Lurie Comprehensive Cancer Center (RHLCCC) of Northwestern University. He is currently Professor and Chair of the Department of Medical Social Sciences at Northwestern University. His research interests and accomplishments are focused in the areas of basic measurement research, descriptive studies of quality of life (QOL) and cancer survival, analysis and interpretation of patient-reported outcomes data in clinical trials, and QOL intervention research. During his 15 years at Northwestern, Dr. Cella has had continuous NIH funding on several projects specifically focused on health-related QOL measurement, analysis, and interpretation in cancer patients. Most recently, he has led the NIH Common Fund Patient reported Outcomes Measurement Information System (PROMIS) as chair of its Steering Committee and PI of its Statistical Center. PROMIS has a major cancer component, sponsored by NCI through the Common Fund and more directly through projects like Dr. Cella's parallel R01, referred to as PROsetta Stone, linking common measures across important life domains such as pain, fatigue, depression, anxiety and physical function. Dr. Cella is heavily engaged in academic and scientific interactions relevant to cancer outside of Northwestern University. He is immediate past chairman of the QOL committee of the Gynecologic Oncology Group, and immediate past chairman of the Patient Outcomes and Survivorship Committee of the Eastern Cooperative Oncology Group. He held these leadership positions in each cooperative group for more than 10 years each, and mentored the current committee leaders into those roles as he transitioned to more leadership responsibility at Northwestern. Dr. Cella has collaborative ties with NSABP, RTOG, EORTC, SWOG, and CALGB. He has co-authored papers with peers from all of these cooperative groups, and has become recognized as an important collaborator and facilitator of progress in this area of QOL measurement, analysis, and interpretation of cancer clinical trial data. In addition to the cooperative group collaborations mentioned above, Dr. Cella is an active member of the National Comprehensive Cancer Network, serves on two guideline panels (fatigue and anemia), and he serves on the NCI Symptom Management and Quality of Life Steering Committee and the NCI Multiple Myeloma Steering Committee. He is also a consultant

and advisor to many cancer centers and cancer treatment programs regarding interactions between cancer prevention and control programs with clinical programs, and outcomes research opportunities within those structures. Dr. Cella is frequently consulted for clinical trial design and analysis, and interpretation of patient-reported outcomes in the context of cancer clinical trials conducted by both NIH and industry. He delivers an average of 1 grand rounds level presentation per month on outcomes research and/or clinical trials at academic medical centers and meetings around the world.

Karen Fields, MD

Co-Chair

Medical Director, Strategic Alliances, Moffitt Cancer Center
Tampa, Florida

Dr. Fields is a medical oncologist who received her medical degree from Ohio State University. Currently at Moffitt Cancer Center, she has also held leadership positions at multiple major cancer centers and has more than 70 scholarly publications.

Gregary Bocsi, DO, FCAP

Associate Director, University of Colorado Hospital Clinical Laboratory
Denver, Colorado

Gregary Bocsi, DO, FCAP, is the Associate Director of University of Colorado Hospital (UCH) Clinical Laboratory and an Assistant Professor in the Department of Pathology at the University of Colorado School of Medicine. His role is clinically oriented with most of his effort allocated as medical director of a few UCH clinical laboratories and to solid tumor analysis at the Colorado Molecular Correlates Laboratory. He is regularly involved in projects and committees related to quality management, process improvement, and optimal utilization of laboratory services. He is active in the education of medical students and pathology residents.

Brent Braveman, Ph.D, OTR/L, FAOTA

Director, Department of Rehabilitation Services, University of Texas M.D. Anderson Cancer Center
Houston Texas

Dr. Braveman is an expert in rehabilitation services in oncology and chronic illness. He has extensive experience in program development, assessment development and outcomes research. He is nationally recognized for expertise in health care reform, social justice and population health. He directs the largest oncology rehabilitation department in the country with over 130 therapy practitioners at five sites. Dr. Braveman recently participated in a NIH Subject Matter Expert Panel on oncology rehabilitation examining practice models and identifying evidence and practical considerations for the use of clinical, functional measurement tools and integration of rehabilitation services into the oncology continuum of care.

Joanne Buzaglo, PhD

Senior Vice President of Research and Training, Cancer Support Community
Philadelphia, Pennsylvania

Joanne Buzaglo, PhD is SVP of Research & Training at the Cancer Support Community's (CSC) Research and Training Institute. She is a health researcher and clinical psychologist. Her focus is on translating research into community-based practice with an emphasis on psychosocial

screening and decision support. She leads the Cancer Experience Registry, a cutting-edge online research initiative tracking patient-reported outcomes to inform and develop innovative programmatic, educational and policy initiatives. As a two-time cancer survivor, Dr. Buzaglo has counseled individuals coping with cancer. Prior to joining CSC, she was the Deputy Director of Fox Chase Cancer Center's Behavioral Research Core Facility.

Jennifer Carney, MD

Chief of Hematology and Oncology and Principle Investigator for Oncology Research Trials,
Hawaii, Kaiser Permanente
Honolulu, Hawaii

Dr. Jennifer Fu Carney is Chief of Hematology/Oncology and Principle Investigator for Kaiser Permanente Hawaii's oncology/hematology research. Her priorities include improving quality across the region, improving access to care for rural populations, and increasing enrollment in clinical trials. She received her MD from University of North Carolina and completed her fellowship at University of Michigan. She was assistant professor at University of Hawaii while completing a master's in clinical research. She serves on inter-regional committees to improve value based oncology care. She was physician lead for implementation of evidence-based, electronic chemotherapy and led in Kaiser Permanente's CoC accreditation and QOPI certification.

Steven Chen, MD, MBA, FACS

Director of Surgical Oncology, OasisMD
San Diego, California

Steven Chen, MD, MBA is a surgical oncologist and health services researcher at the City of Hope National Cancer Center. His clinical interest is focused on breast cancer and endocrine diseases. He received an MBA focused on corporate strategy and operations analysis. Previously he has served as a member of the Care Transitions workgroup and Clinical Decision Support Oncology Workgroup for the Physicians Consortium for Performance Improvement and served on the Cancer Technical Advisory Panel for phase II of the Efficiency:Resource Use project, as well as numerous committee memberships in various professional societies. His research focuses on quality, cost-effectiveness, and outcomes in cancer care, and the greater health care system.

Crawford Clay

Patient Support Navigator & Advocacy Coordinator, Colon Cancer Alliance
Washington DC

In May 2004 I found out that I had stage 3 rectal cancer. That same week I learned my father had colon cancer as well. His father had also had it. I went through radiation, chemotherapy, surgery and more chemotherapy. I finished chemo on Valentine's Day 2005. I had my ileostomy reversed later that spring. I was in treatment for about a year. Since then I have become very involved in many issues touching cancer. I have served as a volunteer chaplain for St. Joseph's Hospital. I've worked in patient support for the Colon Cancer Alliance since 2010.

Matt Facktor, MD, FACS

Director, Department of Thoracic Surgery, Geisinger Medical Center
Danville, Pennsylvania

Dr. Matthew Facktor is the Director of Thoracic Surgery and the Lung Cancer Clinic at Geisinger Medical Center (Danville, PA). Dr. Facktor is a member of the American College of Surgeons

Commission on Cancer, and directs the Commission's Multi-Disciplinary Lung Cancer Collaborative with ProvenCare®. Dr. Facktor has interests in thoracic oncology and the reliable delivery of evidence-based health care. He studied percussion performance at The University of Michigan before completing medical school at Wayne State University (Detroit), general surgery residency at Rush University & Cook County Hospital (Chicago), and thoracic surgery residency at George Washington University (Washington, DC).

Martin Fleisher, PhD, MS

Provider, American Association for Clinical Chemistry
Glen Cove, New York

Dr. Fleisher is former Chairman of the Department of Clinical Laboratories and Chief of the Clinical Chemistry service at the Memorial Sloan-Kettering Cancer Center in New York City. He is currently Director of the Biomarker Discovery Laboratory and Attending Clinical Chemist in the Department of Laboratory Medicine at MSKCC. Dr. Fleisher is internationally recognized as an expert in the discovery and use of tumor markers and biomarkers for detecting and monitoring cancer. Dr. Fleisher has received numerous awards from the AACC and Canadian Society of Clinical Chemists for his outstanding contributions to science and medicine.

Shelley Fuld Nasso, MPP

CEO, National Coalition for Cancer Survivorship
Washington DC

Shelley Fuld Nasso, MPP, is Chief Executive Officer of the National Coalition for Cancer Survivorship. She serves as a member of the National Cancer Institute's National Council of Research Advisors, the American Society of Clinical Oncology's Cancer Survivorship Committee, and the National Quality Forum's Consensus Standards Approval Committee and Measures Application Partnership. Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged Komen's grassroots network to strengthen the organization's reputation and visibility in Washington, D.C., and in state capitals.

Jennifer Harvey, MD, FACP

Professor of Radiology at the University of Virginia Health System, Chief of the Division of Breast Imaging, Co-Director of the UVa Breast Care Program, and Vice-Chair of Faculty Development
University of Virginia Health System
Charlottesville, Virginia

I have served as the head of the division of Breast Imaging at the University of Virginia for over 20 years, and this position requires direct supervision of quality assurance and management of process improvement. Early in my career, I served on the Outpatient Clinical Advisory Panel for the Virginia Health Quality Center (1999-2001). During this time, we set guidelines and expectations for the Commonwealth; I travelled to speak at meetings on these and to review practices to ensure compliance with the evolving BI-RADS guidelines. At the national level, I served on the Joint Committee on Breast Imaging for Appropriateness Criteria and Guidelines/Standards for the American College of Radiology from 2006-2015. This committee was tasked with setting guidelines for practice; I was the primary author on several published guidelines. In addition, I serve as a reviewer for the Breast Ultrasound and Ultrasound-guided Biopsy Accreditation Program for the ACR, since 2006.

Bradford Hirsch, MD

Senior Medical Director, Flatiron Health
New York, New York

Dr. Hirsch is Senior Medical Director for Flatiron Health and a practicing medical oncologist with Texas Oncology in Dallas. At Flatiron Health, he helps to lead multiple efforts including value based care initiatives, collaborations with life sciences companies, and the development of novel research capabilities. Prior to joining Flatiron, he served as Medical Director of informatics and health economics and outcomes research (HEOR) for US Oncology and was on the faculty of the Duke Clinical Research Institute. Across these roles, he focuses on the use of data and novel technologies to advance the frontier in medicine.

Jette Hogenmiller, PhD, MN, APRN/ARNP, CDE, NTP, TNCC, CEE

Oncology Nurse Practitioner
Idaho Springs, Colorado

Dr. Hogenmiller received her graduate degree from the University of Washington, Seattle, in the Oncology pathway. She has two years of public health graduate work, with a focus on cancer epidemiology and vulnerable populations from the University of Michigan. Her PhD is from the University of Nebraska, where she focused on psychometrics (reliable & valid tool development) and oncology. Some of her publications include "Patterns of Pap smear screening in women diagnosed with invasive cervical cancer" in the Journal of Gynecologic Surgery; "Self-efficacy scale for Pap smear screening participant in shelter women in Nursing Research"; and others.

She has developed a number of comprehensive oncology care programs/approaches (e.g. general oncology, gynecologic oncology), in a variety of settings (e.g. university, community-based). Currently she and a medical oncologist are creating two new cancer programs to expand access in a rural and urban setting. As an advanced practice nurse (family/oncology nurse practitioner) she applies her skill set and a number of certifications to provide for holistic cancer care that engages and empowers the patient and family to be full partners in care to maximize healing. Some of her certifications include that of a diabetic educator, nutrition therapy practitioner and trauma nurse, and training in functional medicine. She has served in the Army Nurse Corps for over 21 years.

Joseph Laver, MD, MHA

Chief Medical Officer and Professor of Pediatrics, Stony Brook University Hospital
Stony Brook, New York

Chief Medical Officer and Professor of Pediatrics at Stony Brook Medicine, Stony Brook University Hospital. Previously, positions include Executive Vice President and Clinical Director and Chief of Clinical Operations at St. Jude Children's Research Hospital, Chairman of the Department of Pediatrics at Virginia Commonwealth University Medical Center, Director of Hematology/Oncology and Pediatric Bone Marrow Transplantation and Vice Chairman of the Department of Pediatrics at the Medical University of South Carolina, and Assistant Professor of Pediatrics at Memorial Sloan-Kettering Cancer Center and Cornell University Medical College.

J. Leonard Lichtenfeld, MD, MACP

Deputy Chief Medical Officer, American Cancer Society
Atlanta, Georgia

Dr. Lichtenfeld is Deputy Chief Medical Officer for the American Cancer Society. He joined the

Society in 2001 and in 2002 assumed responsibility for managing the Society's Cancer Control Science Department. In 2014, he assumed his current role in the Office of the Chief Medical Officer. He is a frequent media spokesperson regarding the Society's positions on a number of important issues related to cancer. He has testified on legislative and regulatory issues, and participated on numerous panels regarding cancer care, research, advocacy and related topics. He has a strong interest in issues related to health care including physician payment, medical care delivery systems, and health information technology.

Jennifer Malin, MD, PhD

Staff Vice President, Clinical Strategy, Anthem, Inc.
Thousand Oaks, California

Jennifer Malin, MD, PhD, Staff VP, Clinical Strategy at Anthem, Inc. and Associate Professor of Medicine at the UCLA David Geffen School of Medicine, has authored more than 90 peer-reviewed articles and is widely recognized for her research on the quality of cancer care. She has extensive experience in developing and validating quality indicators for the assessment of all aspects of cancer care and has led multiple studies to evaluate the reliability and validity of measures using diverse data sources. She continues her clinical practice by volunteering at the Veterans Affairs Greater Los Angeles Health Care System.

Jodi Maranchie, MD, FACS

Associate Professor, University of Pittsburgh, Department of Urology
Pittsburgh, Pennsylvania

Dr. Jodi Maranchie is a board-certified urologist and assistant professor of urology at the University of Pittsburgh School of Medicine. Dr. Maranchie graduated from Northwestern University Feinberg School of Medicine and completed urology residencies at Harvard University and Brigham and Women's Hospital in Boston as well as a postdoctoral fellowship in urologic oncology as an American Foundation of Urologic Diseases Scholar at the National Cancer Institute. An active researcher in basic and clinical research of urologic cancers with a special interest in kidney cancer, Dr. Maranchie focuses on cancers of the kidney, testis, bladder and prostate, including reconstructive nerve- and kidney-sparing procedures.

Ali McBride, Pharm.D., M.S., BCPS

Clinical Coordinator, Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center
Tucson, Arizona

Ali McBride, Pharm.D., M.S., BCPS, is the clinical coordinator of Hematology/Oncology at the University of Arizona Cancer Center. His practice and research interests include acute and chronic leukemias, multiple myeloma, infectious diseases, oncologic emergencies, and pharmacogenomics.

Previously, he served as the stem cell transplant pharmacist at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State Medical Center and the hematologic malignancies/stem cell transplant pharmacist at Siteman Cancer Center at Barnes-Jewish Hospital.

Dr. McBride has previously served on the Board of Trustees for the Association of Community Cancer Centers. He has been actively involved with the American Society of Health-System Pharmacists (ASHP), Arizona Pharmacy Association (AzPA) and the Hematology Oncology

Pharmacy Association for which he served as the chair of the Legislative Affairs Committee. He received a B.S. degree in Neurobiology and Physiology from Purdue University, and M.S. in Biology from Indiana University-Purdue University, and a Pharm.D. degree from the University of Arizona College of Pharmacy.

Benjamin Movsas, M.D.

Chair, Radiation Oncology, Henry Ford Health System
Detroit, Michigan

Benjamin Movsas MD serves as Chair of the Henry Ford Hospital Radiation Oncology Department. He has served in many national leadership roles to enhance the quality of cancer care. As Chair of the American College of Radiology Radiation Oncology Appropriateness-Criteria, he developed national consensus measures for multidisciplinary quality cancer care. As co-chair of the National Cancer Institute (NRG) Patient-Centered-Outcomes-Committee, he strives to improve cancer outcomes and quality of life. As Chair of the American Society of Radiation Oncology (ASTRO) Scientific Program, he helps educate colleagues. He has 250 publications which primarily focus on his goal to improve the quality of cancer care.

Diane Otte, RN, MS, OCN

Director, Cancer Center, Mayo Clinic Health System - Franciscan Healthcare
La Crosse, Wisconsin

Ms. Otte is director of the Cancer Center at Mayo Clinic Health System – Franciscan Healthcare in LaCrosse, WI. Her experiences in oncology inpatient, ambulatory, hospice, home care, cancer program administration/management and her volunteer leadership roles within the Oncology Nursing Society (ONS) have focused on improving the quality of care delivered to people with cancer. Her volunteer leadership roles have included serving on the Board of Directors of both ONS and the Oncology Nursing Certification Corporation. She has served as the ONS liaison to the American College of Surgeon's Commission on Cancer and led ONS quality measurement projects.

Beverly Reigle, PhD, RN

Associate Professor, University of Cincinnati College of Nursing
Cincinnati, Ohio

Beverly Reigle, PhD, RN, is an Associate Professor at the University of Cincinnati College of Nursing and Director of the Cancer Survivorship Program at the University of Cincinnati Cancer Institute. Her main clinical and research focus is on cancer care and she has developed oncology-focused courses and conducted breast cancer and survivorship research in addition to teaching courses on quantitative methods and quality improvement and safety. As Director of the Cancer Survivorship Program Dr. Reigle oversees the educational, clinical, and research components of the program.

David J. Sher, MD, MPH

Associate Professor, UT Southwestern Medical Center
Dallas, Texas

I grew up in Cleveland, Ohio and received my Bachelor's and Master's Degrees in biochemistry from Yale University in 1998, and my MD degree from Harvard University in 2003. I completed a residency in radiation oncology at the Harvard Radiation Oncology Program, serving as Chief

Resident in 2007-2008. During residency, I received a Health Services Research Fellowship from AHRQ and received my MPH in 2007. Following residency, I have been a practicing radiation oncologist, focusing on head and neck and thoracic malignancies. My research interests focus on the cost and comparative effectiveness of competing local therapies for cancer.

Danielle Ziernicki, PharmD

Director of Healthcare Quality for Oncology, J&J Healthcare Systems
Horsham, Pennsylvania

Danielle Ziernicki, Pharm.D. is the Director of Health Quality for Oncology at Johnson & Johnson. Dr. Ziernicki ensures Janssen oncology strategies support the U.S. overarching quality and reimbursement direction in the changing healthcare environment. Dr. Ziernicki's breadth of experience includes clinical hospital pharmacy, medical information, health policy, and global regulatory policy and drug development. Dr. Ziernicki is a licensed PA pharmacist and received her B.S. and Pharm.D. degrees at Philadelphia College of Pharmacy, University of the Sciences. Danielle completed a Post-Doctoral Residency in Drug Information at Janssen and holds a graduate certificate in Health Policy from Thomas Jefferson University School of Public Health.